Jul 29, 2019 | Anti-METH antibody, IXT-m200, General News, METH in the news
IXT-m200 produced immediate, dose-dependent, time-dependent changes in primary endpoint parameters of methamphetamine AUC and Cmax LITTLE ROCK, AR, USA, July 29, 2019 — InterveXion Therapeutics, a private clinical-stage biopharmaceutical company developing...
Jul 25, 2019 | METH in the news
Source: Asia’s meth trade is now worth an estimated $61B … with no end to the crisis in sight – CNN
Recent Comments